ImmuPharma plc is a drug discovery and development company. The Company, along with its subsidiaries, is principally engaged in investing in pharmaceutical research and development companies. The Company has operations in Mulhouse, France and Basle, Switzerland. The ImmuPharma plc focuses to develop drugs to treat serious medical conditions. It has five drugs in development to treat: lupus, cancer, severe pain, highly resistant infections, such as methicillin-resistant staphylococcus aureus (MRSA) and inflammatory and allergic disorders. Its wholly owned subsidiaries include ImmuPharma (UK) Limited, which is a holding company; ImmuPharma (France) SA, which is engaged in pharmaceutical research and development, and ImmuPharma AG, which is engaged in pharmaceutical research and development.
17/04/12
Posting of Annual Report and AGM Notice27/03/12
Preliminary Results20/03/12
Notification of Full Year Results29/02/12
Appoints Head of Investor Relations24/01/12
Directors Dealings08/11/11
Notification of Major Interest in Shares03/11/11
LupuzorT granted approval to start phase III01/11/11
Notification of Major Interest in Shares01/11/11
Notification of Major Interest in Shares21/10/11
ImmuPharma regains Lupuzor rights30/09/11
INTERIM RESULTS ANNOUNCEMENT23/09/11
Notification of Interim Results12/07/11
Notification of Major Interest in Shares19/05/11
Result of Annual General Meeting05/05/11
IPP-204106 paper published26/04/11
Annual Report and Accounts & Notice of AGM05/04/11
Preliminary Results30/03/11
Notification of Preliminary Results21/02/11
Update on progress of Phase I/IIa Clinical Trial19/10/10
Immupharma PLC Update on Phase IIa Clinical Trial11/10/10
Immupharma PLC Notification of major interests in11/10/10
Immupharma PLC Additional Listing and Total Voting Rights30/09/10
Immupharma PLC Interim Results28/09/10
Immupharma PLC Notification of Interim Results28/06/10
Immupharma PLC Presentation at the International23/06/10
Immupharma PLC Cephalon initiates critical steps in development23/06/10
Immupharma PLC Replacement of Development release17/06/10
Immupharma PLC Result of AGM10/06/10
Immupharma PLC Annual Report and Accounts19/05/10
Immupharma PLC Initiation Of Phase I/IIA Studies In Cancer19/05/10
Immupharma PLC Preliminary Results08/04/10
Immupharma PLC Best Drug Development Company in Europe Award05/01/10
Immupharma PLC Additional Listing05/01/10
Immupharma PLC ING take 4% stake in ImmuPharma plc03/12/09
Immupharma PLC R&D Symposium at the CNRS in Paris19/11/09
Immupharma PLC Positive Final Lupuzor Trial
Copyright © Proactiveinvestors.co.uk, 2012. All Rights Reserved Design & Development: Tehnicom Computers
